Published in N Engl J Med on September 26, 2002
Aspirin Non-responsiveness and Clopidogrel Endpoint Trial. (ASCET) | NCT00222261
Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med (2012) 6.60
Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48
New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J (2013) 2.81
RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J (2011) 2.40
Atrial Fibrillation and Risk of ST-Segment-Elevation Versus Non-ST-Segment-Elevation Myocardial Infarction: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation (2015) 2.33
Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin North Am (2007) 2.17
Arterial thrombosis--insidious, unpredictable and deadly. Nat Med (2011) 1.96
The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int (2006) 1.47
Cardiac manifestation of the hypereosinophilic syndrome: new insights. Clin Res Cardiol (2010) 1.45
Acute coronary syndromes: diagnosis and management, part I. Mayo Clin Proc (2009) 1.38
Antithrombotic therapy after myocardial infarction. N Engl J Med (2002) 1.12
New anticoagulants: how to deal with treatment failure and bleeding complications. Br J Clin Pharmacol (2011) 1.11
Upper gastrointestinal ulcer in Japanese patients taking low-dose aspirin. J Gastroenterol (2009) 1.10
The new oral anticoagulants. Neth Heart J (2010) 1.06
Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation. Neurology (2012) 1.05
Low-dose aspirin-induced gastrointestinal diseases: past, present, and future. J Gastroenterol (2008) 1.04
Synergistic action between inhibition of P2Y12/P2Y1 and P2Y12/thrombin in ADP- and thrombin-induced human platelet activation. Br J Pharmacol (2004) 1.00
Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc (2014) 1.00
Impact of chronic oral anticoagulation on management and outcomes of patients with acute myocardial infarction: data from the RICO survey. Heart (2005) 0.95
Proportion of fibrin and platelets differs in thrombi on ruptured and eroded coronary atherosclerotic plaques in humans. Heart (2005) 0.95
Anticoagulants: A Review of the Pharmacology, Dosing, and Complications. Curr Emerg Hosp Med Rep (2013) 0.95
Benefit of warfarin compared with aspirin in patients with heart failure in sinus rhythm: a subgroup analysis of WARCEF, a randomized controlled trial. Circ Heart Fail (2013) 0.89
Thrombin inhibition by dabigatran attenuates atherosclerosis in ApoE deficient mice. Arch Med Sci (2014) 0.89
Outcomes associated with warfarin use in older patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device: findings from the ADHERE registry linked to Medicare claims. Clin Cardiol (2012) 0.87
Antithrombotic medication for cardioembolic stroke prevention. Stroke Res Treat (2011) 0.87
Gender differences in aspirin use among adults with coronary heart disease in the United States. J Gen Intern Med (2007) 0.86
Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction. J Biomed Biotechnol (2010) 0.86
Should aspirin be continued in patients started on warfarin? J Gen Intern Med (2004) 0.86
[Use and potential risks of over-the-counter analgesics]. Schmerz (2014) 0.84
Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment. Vasc Health Risk Manag (2013) 0.82
Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation. Int J Clin Pract (2013) 0.81
Hotline update of clinical trials and registries presented at the at the European Society of Cardiology Congress in Paris 2011. Clin Res Cardiol (2011) 0.81
Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction. Thromb J (2008) 0.81
Are the novel anticoagulants better than warfarin for patients with atrial fibrillation? J Thorac Dis (2015) 0.81
Safety and efficacy of targeting platelet proteinase-activated receptors in combination with existing anti-platelet drugs as antithrombotics in mice. Br J Pharmacol (2012) 0.80
The CHADS2 score predicts ischemic stroke in chronic heart failure patients without atrial fibrillation: comparison to other stroke risk scores. Heart Vessels (2016) 0.79
Development of a tool to improve the quality of decision making in atrial fibrillation. BMC Med Inform Decis Mak (2011) 0.78
Anticoagulation after anterior myocardial infarction and the risk of stroke. PLoS One (2010) 0.78
Prescription patterns of oral anticoagulants for patients with non-valvular atrial fibrillation: experience at a Japanese single institution. Heart Vessels (2015) 0.77
National trends in stroke after acute myocardial infarction among Medicare patients in the United States: 1999 to 2010. Am Heart J (2014) 0.77
Direct thrombin inhibitors in cardiovascular disease. Nat Rev Cardiol (2012) 0.77
Oral factor Xa inhibitors for the long-term management of ACS. Nat Rev Cardiol (2012) 0.77
Warfarin, aspirin, or both after myocardial infarction. N Engl J Med (2003) 0.77
Plasminogen activators and ischemic stroke: conditions for acute delivery. Semin Thromb Hemost (2013) 0.77
Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants. Clin Interv Aging (2015) 0.76
Management of low-dose aspirin and clopidogrel in clinical practice: a gastrointestinal perspective. J Gastroenterol (2015) 0.76
Thrombin Generation and Atherothrombosis: What Does the Evidence Indicate? J Am Heart Assoc (2016) 0.76
Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding. ACP J Club (2003) 0.76
New oral anticoagulant agents after ACS. Eur Heart J Acute Cardiovasc Care (2012) 0.76
[Postoperative antithrombotic treatment in diabetic patients]. Clin Res Cardiol (2006) 0.75
Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran. Drug Des Devel Ther (2015) 0.75
The Number Needed to Treat: 25 Years of Trials and Tribulations in Clinical Research. Rambam Maimonides Med J (2015) 0.75
Anticoagulation in Heart Failure: a Review. J Atr Fibrillation (2015) 0.75
Warfarin, aspirin, or both after myocardial infarction. N Engl J Med (2003) 0.75
Balancing antiplatelet and anticoagulant therapies in patients with cardiovascular disease. Cardiol Ther (2013) 0.75
Acute myocardial infarction after switching from warfarin to dabigatran. Oman Med J (2015) 0.75
Gastrointestinal bleeding and anticoagulant or antiplatelet drugs: systematic search for clinical practice guidelines. Medicine (Baltimore) (2015) 0.75
Will oral antithrombin agents replace warfarin? Heart (2004) 0.75
Markers of thrombin generation are associated with myocardial necrosis and left ventricular impairment in patients with ST-elevation myocardial infarction. Thromb J (2015) 0.75
Anticoagulation in Heart Failure: a Review. J Atr Fibrillation (2015) 0.75
Impact of anti-aggregant, anti-coagulant and non-steroidal anti-inflammatory drugs on hospital outcomes in patients with peptic ulcer bleeding. Saudi J Gastroenterol (2014) 0.75
Potential role of rivaroxaban in patients with acute coronary syndrome. Drug Des Devel Ther (2012) 0.75
Inappropriate preinjury warfarin use in trauma patients: A call for a safety initiative. J Postgrad Med (2016) 0.75
Dabigatran, A Direct Thrombin Inhibitor, In Atrial Fibrillation: Is It Already Time For A Change In Oral Anticoagulation Therapy? J Atr Fibrillation (2010) 0.75
Secondary prophylactic treatment and long-term prognosis after TIA and different subtypes of stroke. A 25-year follow-up hospital-based observational study. Brain Behav (2016) 0.75
The "dual-pathway" strategy after acute coronary syndrome: rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial. Cardiovasc Ther (2014) 0.75
Anticoagulants for secondary prevention after acute myocardial infarction: lessons from the past decade. Fundam Clin Pharmacol (2014) 0.75
Warfarin plus aspirin more effective than aspirin alone for secondary prevention of MI. J Fam Pract (2003) 0.75
Novel oral anticoagulants to prevent stroke in atrial fibrillation. Nat Rev Cardiol (2010) 0.75
Can venous thromboembolism navigate the prevention of cardiovascular complications? Ann Transl Med (2015) 0.75
The prognostic effects of ventricular heart rate among patients with permanent atrial fibrillation with and without coronary artery disease: a multicenter prospective observational study. Medicine (Baltimore) (2015) 0.75
Warfarin, aspirin, or both after myocardial infarction. N Engl J Med (2003) 0.75
Combined aspirin and anticoagulant therapy in patients with atrial fibrillation. J Thromb Thrombolysis (2016) 0.75
Long-term impact of secondary preventive treatments in patients with stable angina. Eur J Epidemiol (2011) 0.75
Stroke and Intracranial Hemorrhage in HeartMate II and HeartWare Left Ventricular Assist Devices: A Systematic Review. Neurocrit Care (2017) 0.75
Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med (2006) 7.28
Mediastinitis after coronary artery bypass grafting risk factors and long-term survival. Ann Thorac Surg (2010) 2.60
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol (2012) 2.41
Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost (2014) 2.29
Low heart rates predict incident atrial fibrillation in healthy middle-aged men. Circ Arrhythm Electrophysiol (2013) 2.12
Marine n-3 polyunsaturated fatty acids and coronary heart disease. Part I. Background, epidemiology, animal data, effects on risk factors and safety. Thromb Res (2005) 1.62
Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation. Am J Cardiol (2012) 1.60
Upper normal blood pressures predict incident atrial fibrillation in healthy middle-aged men: a 35-year follow-up study. Hypertension (2012) 1.57
Fasting blood glucose is independently associated with resting and exercise blood pressures and development of elevated blood pressure. J Hypertens (2003) 1.57
Reasons for terminating an exercise test provide independent prognostic information: 2014 apparently healthy men followed for 26 years. Eur Heart J (2005) 1.55
Can global initiative for Chronic Obstructive Lung Disease stage 0 provide prognostic information on long-term mortality in men? Chest (2006) 1.51
Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. Am J Cardiol (2007) 1.48
The association between metabolic syndrome and infarct size in patients with acute myocardial infarction. Scand J Clin Lab Invest (2010) 1.45
Candesartan in the prevention of relapsing atrial fibrillation. Int J Cardiol (2006) 1.45
Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation. Eur Heart J (2013) 1.44
Decreased levels of asymmetric dimethylarginine during acute hyperinsulinemia. Metabolism (2007) 1.42
Less benefit from warfarin in diabetics after myocardial infarction? Cardiology (2008) 1.40
[Deaths in Norwegian police cells from 2003 to 2012]. Tidsskr Nor Laegeforen (2014) 1.39
[Incidence and prevention of occupational electrical accidents]. Tidsskr Nor Laegeforen (2003) 1.38
[Not Available]. Tidsskr Nor Laegeforen (2016) 1.38
Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost (2013) 1.36
Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J (2011) 1.34
Frequency of left ventricular thrombus in patients with anterior wall acute myocardial infarction treated with percutaneous coronary intervention and dual antiplatelet therapy. Am J Cardiol (2010) 1.30
Underdiagnosis of myocardial infarction in COPD - Cardiac Infarction Injury Score (CIIS) in patients hospitalised for COPD exacerbation. Respir Med (2008) 1.27
The role of interleukin-18 in the metabolic syndrome. Cardiovasc Diabetol (2010) 1.23
Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J (2011) 1.23
Prevalence of hereditary ataxia and spastic paraplegia in southeast Norway: a population-based study. Brain (2009) 1.22
Rationale and design of the POSTEMI (postconditioning in ST-elevation myocardial infarction) study. Cardiology (2010) 1.21
Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost (2009) 1.21
Autologous stem cell transplantation in acute myocardial infarction: The ASTAMI randomized controlled trial. Intracoronary transplantation of autologous mononuclear bone marrow cells, study design and safety aspects. Scand Cardiovasc J (2005) 1.21
Patients' experiences with symptoms and needs in the early rehabilitation phase after coronary artery bypass grafting. Eur J Cardiovasc Nurs (2012) 1.17
Consequences of antiepileptic drug withdrawal: a randomized, double-blind study (Akershus Study). Epilepsia (2007) 1.16
High prevalence of atrial fibrillation in long-term endurance cross-country skiers: echocardiographic findings and possible predictors--a 28-30 years follow-up study. Eur J Cardiovasc Prev Rehabil (2010) 1.15
Abnormal glucose regulation in patients with acute ST- elevation myocardial infarction-a cohort study on 224 patients. Cardiovasc Diabetol (2009) 1.15
Silent coronary atheromatosis in type 1 diabetic patients and its relation to long-term glycemic control. Diabetes (2002) 1.14
Gender and socioeconomic status as determinants of waiting time for inpatient surgery in a system with implicit queue management. Health Policy (2002) 1.11
Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine. Metabolism (2004) 1.10
Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res (2002) 1.06
Gender differences in management and outcome of acute myocardial infarctions treated in 2006-2007. Cardiology (2009) 1.01
Influence of long-term intervention with dietary counseling, long-chain n-3 fatty acid supplements, or both on circulating markers of endothelial activation in men with long-standing hyperlipidemia. Am J Clin Nutr (2005) 1.00
General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost (2013) 0.99
Interleukin-18 is a strong predictor of cardiovascular events in elderly men with the metabolic syndrome: synergistic effect of inflammation and hyperglycemia. Diabetes Care (2008) 0.98
Anterior myocardial infarction with acute percutaneous coronary intervention and intracoronary injection of autologous mononuclear bone marrow cells: safety, clinical outcome, and serial changes in left ventricular function during 12-months' follow-up. J Am Coll Cardiol (2008) 0.98
Determinants of cardiac troponin T elevation in COPD exacerbation - a cross-sectional study. BMC Pulm Med (2009) 0.97
Age and stress related phenotypical changes in bone marrow CD34+ cells. Scand J Clin Lab Invest (2009) 0.95
Helicobacter pylori infection and hyperemesis gravidarum: a systematic review and meta-analysis of case-control studies. Acta Obstet Gynecol Scand (2009) 0.94
Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis (2003) 0.94
Effect of diet or very long chain omega-3 fatty acids on progression of atherosclerosis, evaluated by carotid plaques, intima-media thickness and by pulse wave propagation in elderly men with hypercholesterolaemia. Eur J Cardiovasc Prev Rehabil (2006) 0.94
Effect of ischemic postconditioning on infarct size in patients with ST-elevation myocardial infarction treated by primary PCI results of the POSTEMI (POstconditioning in ST-Elevation Myocardial Infarction) randomized trial. J Am Heart Assoc (2014) 0.93
No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice. Scand Cardiovasc J (2002) 0.93
The natural history of epistaxis in patients with hereditary hemorrhagic telangiectasia in the Norwegian population: a cross-sectional study. Am J Rhinol Allergy (2011) 0.93
Surgical strategies for women with pelvic organ prolapse and urinary stress incontinence. Int Urogynecol J (2009) 0.93
Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. Scand Cardiovasc J (2004) 0.92
Genetic variation, gene-expression and circulating levels of matrix metalloproteinase-9 in patients with stable coronary artery disease. Clin Chim Acta (2011) 0.92
ECG changes in patients with acute ethanol intoxication. Scand Cardiovasc J (2007) 0.91
Blood cell gene expression associated with cellular stress defense is modulated by antioxidant-rich food in a randomised controlled clinical trial of male smokers. BMC Med (2010) 0.91
Exercise testing of healthy men in a new perspective: from diagnosis to prognosis. Eur Heart J (2004) 0.90
Components of the interleukin-6 transsignalling system are associated with the metabolic syndrome, endothelial dysfunction and arterial stiffness. Metabolism (2013) 0.90
Importance of physical fitness on predictive effect of body mass index and weight gain on incident atrial fibrillation in healthy middle-age men. Am J Cardiol (2012) 0.90
Regional myocardial function after intracoronary bone marrow cell injection in reperfused anterior wall infarction - a cardiovascular magnetic resonance tagging study. J Cardiovasc Magn Reson (2011) 0.89
High On-Aspirin Platelet Reactivity and Clinical Outcome in Patients With Stable Coronary Artery Disease: Results From ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial). J Am Heart Assoc (2012) 0.89
MRI of the median nerve and median artery in the carpal tunnel: prevalence of their anatomical variations and clinical significance. Surg Radiol Anat (2009) 0.88
Circulating levels of IL-18 are significantly influenced by the IL-18 +183 A/G polymorphism in coronary artery disease patients with diabetes type 2 and the metabolic syndrome: an observational study. Cardiovasc Diabetol (2011) 0.88
Supplementation with fish oil affects the association between very long-chain n-3 polyunsaturated fatty acids in serum non-esterified fatty acids and soluble vascular cell adhesion molecule-1. Clin Sci (Lond) (2003) 0.88
The effect of exercise on serum levels of interleukin-18 and components of the metabolic syndrome. Metab Syndr Relat Disord (2009) 0.87
Atrial fibrillation and antithrombotic therapy in a 75-year-old population. Cardiology (2007) 0.86
Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis (2002) 0.86
Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. Eur J Heart Fail (2013) 0.86
Influence of aspirin on inflammatory markers in patients after acute myocardial infarction. Am J Cardiol (2003) 0.86
C-reactive protein predicts death in patients with previous premature myocardial infarction--a 10 year follow-up study. Atherosclerosis (2002) 0.85
Increased levels of CRP and MCP-1 are associated with previously unknown abnormal glucose regulation in patients with acute STEMI: a cohort study. Cardiovasc Diabetol (2010) 0.85
Serum levels of interleukin-18 are reduced by diet and n-3 fatty acid intervention in elderly high-risk men. Metabolism (2009) 0.85
Gender differences of polymorphisms in the TF and TFPI genes, as related to phenotypes in patients with coronary heart disease and type-2 diabetes. Thromb J (2010) 0.85
Helicobacter pylori infection and Hyperemesis gravidarum. An institution-based case-control study. Eur J Epidemiol (2008) 0.85
Bowel magnetic resonance imaging of pediatric patients with oral mannitol MRI compared to endoscopy and intestinal ultrasound. Eur Radiol (2005) 0.84
Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease. Thromb Res (2002) 0.84
Vitamin C consumption is associated with less progression in carotid intima media thickness in elderly men: A 3-year intervention study. Nutr Metab Cardiovasc Dis (2008) 0.84
A long-term follow-up study of chest pain patients: effect of panic disorder on mortality, morbidity, and quality of life. Cardiology (2007) 0.84
Effects of a home-based intervention program on anxiety and depression 6 months after coronary artery bypass grafting: a randomized controlled trial. J Psychosom Res (2007) 0.84
The profile of circulating metalloproteinases after PCI in patients with acute myocardial infarction or stable angina. Thromb Res (2009) 0.84